Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Cancer Research

• Publication date

  1990-07-15

• Fields of study

  Medicine

• Identifiers
  PMID 2194652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

  1989cited by this paper
• Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability

  1989cited by this paper
• Phenytoin pharmacokinetics in critically ill trauma patients

  1988cited by this paper
• Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.

  1987cited by this paper
• Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy.

  1986cited by this paper
• Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

  1986influential reference
• Performance of Bayesian feedback to forecast lidocaine serum concentration: Evaluation of the prediction error and the prediction interval

  1985cited by this paper
• Clinical studies with computer-assisted initial lidocaine therapy.

  1984cited by this paper
• High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection.

  1984cited by this paper
• Rationale for the use of alternating non-cross-resistant chemotherapy.

  1982cited by this paper
• Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.

  1982cited by this paper
• Predicting individual phenytoin dosage

  1981cited by this paper
• VM‐26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia

  1980cited by this paper
• A program package for simulation and parameter estimation in pharmacokinetic systems.

  1979cited by this paper
• VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).

  1979cited by this paper
• Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.

  1977cited by this paper

• Plasma Methotrexate, Red Blood Cell Methotrexate, and Red Blood Cell Folate Values and Outcome in Children With Precursor B-acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

  2012cites this paper
• Dose-toxicity models in oncology

  2011cites this paper
• Optimisation du processus de développement du médicament grâce à la modélisation PK et les simulations d’études cliniques

  2011cites this paper
• A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

  2007cites this paper
• A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

  2007cites this paper
• Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia

  2006cites this paper
• Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

  2005cites this paper
• Pharmacokinetic studies in children with cancer.

  2004cites this paper
• Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents

  2004cites this paper
• Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia

  2004cites this paper
• Populations-Pharmakokinetik und individuelle Dosisanpassung

  2003cites this paper
• Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

  2002cites this paper
• Réflexions pour la mise en place d'un projet global de suivi thérapeutique des anticancéreux

  2002influential citation
• Pharmacodynamics of cancer chemotherapy: childhood ALL as a model

  2001cites this paper
• Adaptive Control Methods for the Dose Individualisation of Anticancer Agents

  2000cites this paper
• EFEITOS CITOTÓXICOS DO TENIPOSIDE, UM DERIVADO SEMI-SINTÉTICO DAS EPIPODOFILOTOXINAS, SOBRE LINHAGENS CELULARES DE CARCINOMA RENAL HUMANO

  2000cites this paper
• Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach

  1999cites this paper
• Bayesian Forecasting in Paediatric Populations

  1996cites this paper
• Etoposide for the treatment of paediatric tumours: what is the best way to give it?

  1996cites this paper
• Renal Function and Methotrexate Clearance in Children With Newly Diagnosed Leukemia

  1995cites this paper
• Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.

  1995cites this paper
• Population and Bayesian pharmacokinetics in oncology.

  1994cites this paper
• Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.

  1994cites this paper
• Pharmacokinetic Drug Interactions with Anticancer Drugs

  1994cites this paper
• Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.

  1993cites this paper
• Individualizing dosing of cancer chemotherapy.

  1993cites this paper
• Therapeutic drug monitoring in cancer management.

  1993cites this paper
• Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.

  1993cites this paper
• Bayesian Estimation and Population Pharmacokinetic Parameters of High Dose Methotrexate in Osteosarcoma

  1993cites this paper
• Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia.

  1993cites this paper
• TherapeuticDrugMonitoring in CancerManagement

  1993cites this paper
• Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.

  1992cites this paper
• Bayesian Parameter Estimation and Population Pharmacokinetics

  1992cites this paper
• Increased teniposide clearance with concomitant anticonvulsant therapy.

  1992cites this paper
• Childhood acute lymphoblastic leukemia with both t(1;19) and t(9;22).

  1992cites this paper
• Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs.

  1991cites this paper
• Targeted Systemic Exposure for Pediatric Cancer Therapy

  1991cites this paper
• A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.

  1991cites this paper